Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting the genomic science, reimbursement discussions, and clinical-trial data buried inside GeneDx’s SEC disclosures can feel like decoding DNA itself. From recognizing revenue tied to whole-genome tests to tracking how rapid NICU sequencing affects margins, the company’s reports are dense with technical language. That’s why investors searching for “GeneDx SEC filings explained simply” start here.
Stock Titan’s platform turns those complexities into clarity. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, and 8-K material events the moment they hit EDGAR, then serves up concise highlights. Need the “GeneDx annual report 10-K simplified” to see year-over-year R&D spending? Done. Curious about clinical-trial milestones disclosed in an 8-K? They’re distilled in seconds—“GeneDx 8-K material events explained.” Real-time alerts flag each “GeneDx Form 4 insider transactions real-time,” letting you monitor “GeneDx executive stock transactions Form 4” without combing filings. Our summaries also connect reimbursement risk factors to revenue trends, so “GeneDx earnings report filing analysis” becomes a quick read instead of a weekend project.
Every filing type unlocks a different lens on this precision-medicine pioneer: the “GeneDx quarterly earnings report 10-Q filing” reveals test-volume growth; the “GeneDx proxy statement executive compensation” shows how leadership is incentivized to expand the rare-disease dataset; “GeneDx insider trading Form 4 transactions” expose buying or selling before pivotal FDA updates. With AI-powered summaries, expert context, and real-time coverage of all forms, understanding GeneDx’s path—from lab bench to bedside—is finally straightforward. Investors use these insights to spot emerging reimbursement trends, evaluate cash burn, and benchmark genomic-data assets—all without wading through hundreds of pages. For anyone “understanding GeneDx SEC documents with AI,” this is the single page to bookmark.
Insider Trading Activity Report: Eli Casdin, Director and 10% owner of GeneDx Holdings (WGS), reported multiple transactions on June 18, 2025. The transactions involved Restricted Stock Units (RSUs) and Class A Common Stock:
- Acquired 3,576 new RSUs that vest at the earlier of next annual meeting or first grant anniversary
- Converted 12,924 RSUs into Class A Common Stock at $0 exercise price
- Currently holds beneficial ownership of: - 20,518 shares directly - 3,507,164 shares through Casdin Partners Master Fund - 19,247 shares through Casdin Partners GP - 333,144 shares through CMLS Holdings
The filing indicates significant insider ownership through various investment vehicles, with Casdin maintaining substantial control through multiple entities where he serves in management positions. The transaction was reported within the required timeframe through an attorney-in-fact.
Keith A. Meister, Director and 10% Owner of GeneDx Holdings, reported multiple transactions in company securities on June 18, 2025:
- Acquired 12,924 shares of Class A Common Stock through the conversion of Restricted Stock Units (RSUs) at $0 cost
- Received a new grant of 3,576 RSUs that will vest at the earlier of next annual shareholder meeting or first grant anniversary
- Following transactions, directly owns 20,129 shares and indirectly controls 3,674,913 shares
Indirect ownership includes 333,144 shares through CMLS Holdings LLC, where Meister serves on Board of Managers, and 3,341,769 shares through Corvex Management LP, where he controls the general partner. The transactions demonstrate continued insider investment aligned with long-term shareholder interests.
Director Jason Ryan of GeneDx Holdings reported multiple transactions in Class A Common Stock on June 18, 2025:
- Acquired 12,924 shares through the conversion of Restricted Stock Units (RSUs) at $0 cost, resulting in direct ownership of 13,054 shares
- Received a new grant of 3,576 RSUs that will vest at the earlier of next annual shareholder meeting or first grant anniversary
- Maintains indirect ownership of 141,356 shares through the Jason Ryan 2024 GRAT
The RSUs represent a contingent right to receive one share of Class A Common Stock upon settlement without consideration. The filing demonstrates continued equity-based compensation for board service and significant insider ownership through both direct holdings and a grantor retained annuity trust structure.
GeneDx Holdings Corp. (WGS) director Emily M. Leproust reported multiple transactions involving Restricted Stock Units (RSUs) on June 18, 2025:
- Acquired 3,576 new RSUs that vest at the earlier of next annual shareholder meeting or first grant anniversary
- Converted 12,924 RSUs into Class A Common Stock at $0 exercise price
- Following these transactions, directly owns 21,276 shares of Class A Common Stock and 3,576 RSUs
These transactions appear to be part of the company's director compensation program, with RSUs converting to common stock upon vesting. The RSUs represent a contingent right to receive one share of Class A Common Stock upon settlement without consideration. All transactions were reported via Form 4 filing through an attorney-in-fact on June 23, 2025.
GeneDx Holdings Corp (WGS) director Richard C. Pfenniger Jr. reported multiple transactions involving Restricted Stock Units (RSUs) on June 18, 2025:
- Acquired 3,576 new RSUs that vest at the earlier of next annual shareholder meeting or first grant anniversary
- Converted 12,924 RSUs into Class A Common Stock at $0 exercise price
- Following these transactions, Pfenniger directly owns 41,506 shares of Class A Common Stock and 3,576 RSUs
The transactions were executed under standard director compensation arrangements, with RSUs representing contingent rights to receive one share of Class A Common Stock upon settlement. The filing was submitted by attorney-in-fact Bridget Brown on June 23, 2025.
GeneDx Holdings Corp. (WGS) director Joshua Ruch reported multiple transactions in a Form 4 filing dated June 28, 2025. Key transactions include:
- Acquisition of 12,924 shares of Class A Common Stock through the conversion of Restricted Stock Units (RSUs) on June 18, 2025, at $0 cost
- Receipt of 3,576 new RSUs on June 18, 2025, which vest at the earlier of next annual shareholder meeting or first grant anniversary
Following these transactions, Ruch's beneficial ownership consists of:
- 29,723 shares held directly
- 194,267 shares held indirectly through various entities: - 14,845 via Kariba LLC - 30,138 via Rugu2 LLC - 149,284 via VAAL Investment Partners Q9 LP
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
What is the core business of GeneDx Holdings Corp?
How does GeneDx support precision medicine?
What types of services does GeneDx offer?
How does GeneDx integrate with healthcare systems?
What sets GeneDx apart from its competitors?
Who are the primary users of GeneDx's services?
How does GeneDx contribute to scientific research?
What is the significance of rapid whole genome sequencing in GeneDx's offerings?
